EUVIMEDEUVIMED entdecken
Übersichtsarbeit

New‐onset and relapsed thrombotic microangiopathy post‐COVID‐19 vaccination

Qiqi Ma iD, Gaosi Xu iD

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28946 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Qiqi Ma und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Donghu District, China. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, COVID-19, Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombotic microangiopathy (TMA) associated with coronavirus disease 2019 (COVID‐19) vaccination has been reported, however, the clinical characteristics and pathogenesis remained mysterious. We reviewed 84 TMA cases post‐COVID‐19 vaccination, including 64 patients diagnosed with thrombotic thrombocytopenic purpura (TTP), 17 cases presented as atypical hemolytic uremic syndrome (aHUS), and three cases manifested as unclassified TMA. TMA episodes were mostly associated with messenger RNA vaccines. For TTP, 67.6% of females developed symptoms after the first dose of the vaccine, and 63.0% of males were secondary to the second dose ( p = 0.015). Compared with TTP, aHUS generally appeared within 7 days ( p = 0.002) and showed higher levels of serum creatinine ( p < 0.001). 87.5% of TTP received plasma exchange (PEX)‐based treatment, and 52.9% of aHUS adopted non‐PEX‐based therapies ( p < 0.001). Mechanistically, complement dysfunction, neutrophil activation, and the generation of pathogenic autoantibodies resulting from molecular mimicry contribute to explaining the pathogenesis of TMA post‐COVID‐19 vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicCOVID-19Thrombotic MicroangiopathiesAtypical Hemolytic Uremic SyndromeMaleFemaleHumansCOVID-19 VaccinesVaccination

Stichwörter der Autor:innen

COVID-19atypical hemolytic uremic syndromethrombotic microangiopathythrombotic thrombocytopenic purpuravaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Donghu District, China.

ORCID-Profile: Qiqi Ma, Gaosi Xu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ma, Q., & Xu, G. (2023). New‐onset and relapsed thrombotic microangiopathy post‐COVID‐19 vaccination. Journal of Medical Virology. https://doi.org/10.1002/jmv.28946

Vancouver

Ma Q, Xu G. New‐onset and relapsed thrombotic microangiopathy post‐COVID‐19 vaccination. Journal of Medical Virology. 2023. doi:10.1002/jmv.28946

BibTeX
@article{Ma2023,
  author = {Ma, Qiqi and Xu, Gaosi},
  title = {New‐onset and relapsed thrombotic microangiopathy post‐COVID‐19 vaccination},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28946}
}
Kostenlos starten →